Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population
Received 23 September 2008; accepted 28 July 2009. published online 21 October 2009.
Abstract
Peroxisome proliferator–activated receptor–γ2 (PPARG2) is a nuclear hormone receptor of ligand-dependent transcription factor involved in adipogenesis and a molecular target of the insulin sensitizers thiazolidinediones. We addressed the question of whether the 3 variants (−1279G/A, Pro12Ala, and His478His) in the PPARG2 gene are associated with type 2 diabetes mellitus and its related traits in a South Indian population. The study subjects (1000 type 2 diabetes mellitus and 1000 normal–glucose-tolerant subjects) were chosen randomly from the Chennai Urban Rural Epidemiology Study, an ongoing population-based study in southern India. The variants were screened by single-stranded conformational variant, direct sequencing, and restriction fragment length polymorphism. Linkage disequilibrium was estimated from the estimates of haplotypic frequencies. The −1279G/A, Pro12Ala, and His478His variants of the PPARG2 gene were not associated with type 2 diabetes mellitus. However, the 2-loci analyses showed that, in the presence of Pro/Pro genotype of the Pro12Ala variant, the −1279G/A promoter variant showed increased susceptibility to type 2 diabetes mellitus (odds ratio, 2.092; 95% confidence interval, 1.22-3.59; P = .008), whereas in the presence of 12Ala allele, the −1279G/A showed a protective effect against type 2 diabetes mellitus (odds ratio, 0.270; 95% confidence interval, 0.15-0.49; P < .0001). The 3-loci haplotype analysis showed that the A-Ala-T (−1279G/A-Pro12Ala-His478His) haplotype was associated with a reduced risk of type 2 diabetes mellitus (P < .0001). Although our data indicate that the PPARG2 gene variants, independently, have no association with type 2 diabetes mellitus, the 2-loci genotype analysis involving −1279G/A and Pro12Ala variants and the 3-loci haplotype analysis have shown a significant association with type 2 diabetes mellitus in this South Indian population.
aMadras Diabetes Research Foundation, Gopalapuram, Chennai 600 086, India
bDr Mohan’s Diabetes Specialities Centre, Chennai 600 086, India
cMRC Epidemiology Unit, Institute of Metabolic Science, Cambridge CB2 0QQ, UK
dIndian Statistical Institute, Kolkata 700108, India
eJawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560 064, India
fDepartment of Biochemistry, Indian Institute of Science, Bangalore 560012, India
Corresponding author. Department of Molecular Genetics, Madras Diabetes Research Foundation, Gopalapuram, Chennai 600 086, India. Tel.: +91 9144 2835 9048; fax: +91 9144 2835 0935.